Impact of Repeated Cycles of EGF Bispecific Angiotoxin (eBAT) Administered at a Reduced Interval from Doxorubicin Chemotherapy in Dogs with Splenic Hemangiosarcoma.
Sign Up to like & getrecommendations! Published in 2020 at "Veterinary and comparative oncology"
DOI: 10.1111/vco.12590
Abstract: We previously reported that eBAT, an EGF-targeted angiotoxin, was safe and improved overall survival for dogs with splenic hemangiosarcoma when added to the standard of care in a single cycle of three administrations in the… read more here.
Keywords: chemotherapy; angiotoxin; splenic hemangiosarcoma; dogs splenic ... See more keywords
Canine splenic hemangiosarcoma cells express and activate luteinizing hormone receptors in vitro.
Sign Up to like & getrecommendations! Published in 2022 at "American journal of veterinary research"
DOI: 10.2460/ajvr.22.07.0120
Abstract: OBJECTIVE To determine luteinizing hormone receptor (LHR) expression and response to LHR activation in isolated canine splenic hemangiosarcoma cell lines in vitro. SAMPLES In vitro cultures of commercially available canine splenic hemangiosarcoma cell lines (EFS,… read more here.
Keywords: cell; canine splenic; splenic hemangiosarcoma; luteinizing hormone ... See more keywords
Histopathological Grading, Clinical Staging and CD 31 Expression of Canine Splenic Hemangiosarcoma
Sign Up to like & getrecommendations! Published in 2023 at "Veterinary Sciences"
DOI: 10.3390/vetsci10030190
Abstract: Simple Summary Canine hemangiosarcoma is an aggressive cancer with a short median survival time, commonly found in the spleen of older dogs. There are limited tests available to provide clinically useful prognostic information to guide… read more here.
Keywords: canine splenic; splenic hemangiosarcoma; expression; tumor ... See more keywords